FDA: No Evidence Supports Continuation of Oral Drugs in Relapsed COVID Patients
- ‘Cancer-Shattering’ Method Targets Non-Coding Sequences to Eradicate Brain Tumors
- What is HIV Post-Exposure Prophylaxis (PEP)?
- Moderna Team Detects No Uptake of mRNA-LNPs in Muscles at Injection Site
- Vitamin B5 Found to Promote Cancer Growth
- Harmful Chemical D5 Found in Common Hair Care Products
- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
FDA: No Evidence Supports Continuation of Oral Drugs in Relapsed COVID Patients
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA: No Evidence Supports Continuation of Oral Drugs in Relapsed COVID Patients
The U.S. Food and Drug Administration (FDA) said on Thursday (May 5) that there is currently “no evidence” to support patients who have relapsed from the coronavirus taking a second course of Pfizer’s oral Covid-19 drug will help their condition.
FDA officials say there is currently “no evidence” to support patients with relapsed coronavirus disease taking a second course of Pfizer’s oral Covid-19 drug will help their condition.
According to a report yesterday, the US pharmaceutical company Pfizer said that after completing the course of the oral drug Paxlovid, patients with coronary disease should continue to take the drug if they face the recurrence of symptoms of the coronavirus. Under current U.S. regulatory agency guidelines, people are limited to taking it for five consecutive days.
Some COVID-19 patients are unable to eliminate the virus after completing the course of oral COVID-19 medication for unknown reasons.
With coronavirus load levels rebounding, “you should use a second course of treatment, just like you would with antibiotics,” said Pfizer President Aberdeen.
Peng News reported that Farley, director of the Office of Infectious Diseases at the FDA’s Center for Drug Evaluation and Research, wrote on his official website on Wednesday (May 4) that there is currently no data to support a longer course of treatment or taking a second five-day course of oral medication. Helps to treat or prevent the recurrence of coronavirus. “We will continue to review data from clinical trials and will provide more information in due course.”
The FDA granted emergency use authorization for Paxlovid late last year, but the oral drug has not yet received full approval. Authorities’ current prescribing guidelines suggest the oral drug is not authorized for people to take for more than five days in a row.
FDA: No Evidence Supports Continuation of Oral Drugs in Relapsed COVID Patients
(source:internet, reference only)
Disclaimer of medicaltrend.org
